MnDPDP for MR imaging of the liver: Results from the European phase III studies

Acta Radiologica

Volumn 38, Issue 4 PART 2, 1997, Pages 631-637

  Torres, Carl G ^a   Lundby, B ^a   Tufte Sterud, A ^a   Mcgill, S ^a   Gordon, P B ^a   Strand Bjerknes, H ^a  

^a NYCOMED IMAGING AS   (Norway)

Author keywords

Contrast media; Efficacy; Liver; MR imaging; Safety

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; EDETIC ACID; MANGANESE; N,N' BIS(PYRIDOXAL 5 PHOSPHATE)ETHYLENEDIAMINE N,N' DIACETIC ACID; N,N'-BIS(PYRIDOXAL-5-PHOSPHATE)ETHYLENEDIAMINE-N,N'-DIACETIC ACID; PYRIDOXAL 5 PHOSPHATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; EUROPE; FEMALE; HUMAN; INSTRUMENTATION; LIVER; LIVER TUMOR; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHASE 3 CLINICAL TRIAL; SAFETY; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; EDETIC ACID; EUROPE; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MANGANESE; MIDDLE AGED; PYRIDOXAL PHOSPHATE; SAFETY;

EID: 0031179877     PISSN: 02841851     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841859709172393     Document Type: Article

References (11)

1. BERNARDINO M. E., YOUNG S. W., LEE J. K. T. & WEINREB J. C.: Hepatic MR imaging with MnDPDP. Safety, image quality, and sensitivity. Radiology 183 (1992), 53.
2. EGGLIN T. K., RUMMENY E., STARK D. D., WITTENBERG J., SAINI S. & FERRUCCI J. T.: Hepatic tumors. Quantitative tissue characterization with MR imaging. Radiology 176 (1990), 107.
3. ELIZONDO G., FRETZ C. J., STARK D. D. et al.: Preclinical evaluation of MnDPDP. New paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 178 (1991), 73.
4. HAMM B., STAKS T., MÜHLER A. et al.: Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent. Safety, pharmacokinetics, and MR imaging. Radiology 195 (1995), 785.
5. KOTZ S. & JOHNSON N. L.: Encyclopaedia of statistical sciences, vol. 5. John Wiley & Sons, New York 1985.
6. RUMMENY E., EHRENHEIM C., GEHL H. B. et al.: Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors. Results of clinical phase II trials in Germany including 141 patients. Invest. Radiol. 26 (1991), S142.
7. RUMMENY E. J., TORRES C. G., KURDZIEL J. C., NILSEN G., OP DE BEECK B. & LUNDBY B.: MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies. Acta Radiol. 38 (1997), 638.
8. RUMMENY E. J., WERNECKE K., SAINI S. et al.: Comparison between high-field-strength MR imaging and CT for screening of hepatic metastases. An receiver operating characteristic analysis. Radiology 182 (1992), 879.
9. SCHWARTZ L. H., SELTZER S. E., TEMPANY C. M. C. et al.: Superparamagnetic iron oxide hepatic MR imaging. Efficacy and safety using conventional and fast spin-echo pulse sequences. J. Magn. Reson. Imaging 5 (1995), 566.
10. SUGARBAKER P. H., NELSON R. C., MURRAY D. R., CHEZMAR J. L. & BERNADINO M. E.: A segmental approach to computerized tomographic portography for hepatic resection. Surg. Gynecol. Obstet. 171 (1990), 189.
11. VASSILIADES V. G., FOLEY W. D., ALARCON J. et al.: Hepatic metastases. CT versus MR imaging at 1.5 T. Gastrointest. Radiol. 16 (1991), 159.